At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.
Several cell therapy presentations will vie for attention at Ash, though today the spotlight falls on Autolus.
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
With many of the usual targets on display Fate, Celyad, Allovir and others look to maintain momentum.
Adaptimmune and Allogene led numerous cell therapy companies higher over the Asco period, while Cytomx and Arvinas suffered the biggest losses.
On the corporate front Astellas continued to buy, while Qiagen decided that it was not, after all, up for sale.
Nextcure’s Society for Immunotherapy of Cancer presentation gave investors little reason for cheer, but there's better news for Pieris, Celyad and Nektar.